Get started
Author

Philip Räth

Observed names: P. Raeth, P. Räth, Philip Raeth
Institution: Bundeskriminalamt
Observed institution: Bundeskriminalamt
ORCID: 0009-0009-6715-6337
Observed ORCID: 0009-0009-6715-6337
OpenAlex ID: A5109713089
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
2023 · N. Harbeck, P.A. Fasching, et al. · Annals of Oncology · 51
PDF
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy
2023 · Nadia Harbeck, Ronald Kates, et al. · Cancer Treatment Reviews · 15
CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.
2023 · Nadia Harbeck, Peter A. Fasching, et al. · Journal of Clinical Oncology · 10
PDF
Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al. · Clinical Cancer Research · 3
Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.
2023 · Ramona Erber, Hans-Christian Kolberg, et al. · Journal of Clinical Oncology · 3
PDF
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
2026 · Oleg Gluz, Ulrike A. Nitz, et al. · Journal of Clinical Oncology · 2
Abstract PS16-01: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer (TNBC) – final analysis of the neoadjuvant neoMono trial
2024 · Hans-Christian Kolberg, Johannes Schumacher, et al. · Cancer Research · 2
Data from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Supplementary Table S1 from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Supplementary Table S2 from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Supplementary Table S3 from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Supplementary Table S5 from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Supplementary Table S4 from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Supplementary Table S7 from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Supplementary Table S6 from Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer—The neoMono Trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al.
Abstract PS17-07: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in high-risk triple-negative breast cancer (TNBC) – a subgroup analysis of the neoadjuvant neoMono trial
2025 · Hans-Christian Kolberg, Johannes Schumacher, et al. · Clinical Cancer Research
Abstract P2-11-17: Atezolizumab in combination w/ polychemotherapy w/ or without a pretherapeutic immune therapy window in patients w/ early triple negative breast cancer (eTNBC) & low tumor burden – prospective data from the randomized neoadjuvant neoMono trial
2025 · Cornelia Kolberg-Liedtke, Johannes Schumacher, et al. · Clinical Cancer Research
195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy
2023 · N. Harbeck, R.E. Kates, et al. · ESMO Open
PDF
Works count: 18
Citation count: 86
H-index: 3
I10-index: 3
Year
Topic
Type